Background:  This is a randomized, superiority, double blind, placebo-controlled, multicenter study comparing evolocumab 420mg  SC vs. placebo administered in the acute phase of ACS. The aim is to evaluate the effectiveness of the PCSK9 inhibitor  evolocumab as compared with placebo for reduction of LDL-C levels within 8 weeks in patients receiving guideline-  recommended high-intensity statin treatment (atorvastatin 40mg QD).   Sponsor: Inselspital Bern, Prof. Dr. Stephan Windecker  Trial Registration No: NCT03287609 (clinicaltrials.gov) Link  Trial Status: recruiting  Enrolling Centers:  Bern, Basel, Fribourg, Genf, Lausanne, Lugano, Zürich  Core Study Team: 
© Christian Mueller, 2012 - 2018 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: Juni 2018
Beate Hartmann Ph.D. Jasmin Martin Dayana Flores Rahel Isenrich Home News Team Studies Publications Events Cooperations Contact Max Rieger Kristin Podkowik Bettina Glatz Brigitte Fitze Michael Freese Aymann Alhussini Stephanie Dörflinger Romy Mayr